Oppenheimer Holdings, Inc. Reaffirms “Buy” Rating for Eiger BioPharmaceuticals, Inc. (EIGR)
Oppenheimer Holdings, Inc. reiterated their buy rating on shares of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) in a research note published on Monday morning. They currently have a $34.00 target price on the biotechnology company’s stock.
Several other research firms have also issued reports on EIGR. ValuEngine upgraded shares of Eiger BioPharmaceuticals from a strong sell rating to a sell rating in a report on Friday, September 1st. Zacks Investment Research lowered shares of Eiger BioPharmaceuticals from a hold rating to a sell rating in a report on Wednesday, July 26th. Wedbush restated an ourperform rating and issued a $34.00 target price on shares of Eiger BioPharmaceuticals in a report on Monday, August 14th. Piper Jaffray Companies restated a buy rating and issued a $36.00 target price on shares of Eiger BioPharmaceuticals in a report on Tuesday, August 15th. Finally, BTIG Research began coverage on shares of Eiger BioPharmaceuticals in a report on Friday, July 14th. They issued a buy rating and a $32.00 target price for the company. Two analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. The stock presently has an average rating of Hold and an average target price of $28.46.
Eiger BioPharmaceuticals (NASDAQ:EIGR) traded down 0.6721% during trading on Monday, hitting $10.8764. 957 shares of the company’s stock were exchanged. Eiger BioPharmaceuticals has a 52-week low of $6.10 and a 52-week high of $14.75. The firm has a 50 day moving average price of $8.93 and a 200 day moving average price of $8.60. The company’s market cap is $91.00 million.
Eiger BioPharmaceuticals (NASDAQ:EIGR) last released its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($1.33) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.28) by ($0.05). On average, equities research analysts predict that Eiger BioPharmaceuticals will post ($5.21) earnings per share for the current year.
In other Eiger BioPharmaceuticals news, Director Jeffrey S. Glenn bought 15,000 shares of the business’s stock in a transaction on Friday, September 1st. The shares were acquired at an average price of $9.53 per share, with a total value of $142,950.00. Following the transaction, the director now owns 31,355 shares of the company’s stock, valued at approximately $298,813.15. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 28.80% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Hikari Power Ltd increased its position in Eiger BioPharmaceuticals by 491.0% during the 2nd quarter. Hikari Power Ltd now owns 60,992 shares of the biotechnology company’s stock valued at $482,000 after purchasing an additional 50,672 shares during the period. Goldman Sachs Group Inc. purchased a new position in shares of Eiger BioPharmaceuticals in the 2nd quarter worth approximately $272,000. LMR Partners LLP purchased a new position in shares of Eiger BioPharmaceuticals in the 2nd quarter worth approximately $116,000. Bank of New York Mellon Corp grew its position in shares of Eiger BioPharmaceuticals by 6.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 14,567 shares of the biotechnology company’s stock worth $115,000 after buying an additional 871 shares during the last quarter. Finally, Susquehanna International Group LLP purchased a new position in shares of Eiger BioPharmaceuticals in the 2nd quarter worth approximately $114,000. 59.94% of the stock is currently owned by institutional investors and hedge funds.
Eiger BioPharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.
Receive News & Stock Ratings for Eiger BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals Inc. and related stocks with our FREE daily email newsletter.